Additionally, while our study addressed the relative safety of early P2Y12 inhibition discontinuation irrespective of cancer stage and treatment, our time frame was insufficient to address the interesting aspect of prolonged (>1 year) P2Y12 inhibition and its impact on cancer or cardiovascular mortality (51). Here, P2RY12 is linked to cancer.